Keloids (Dermatology) - Drugs in Development, 2021
![](/report_cover/2671/keloids-dermatology-drugs-in-development-2021_en.gif)
Keloids (Dermatology) - Drugs in Development, 2021
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keloids - Drugs In Development, 2021, provides an overview of the Keloids (Dermatology) pipeline landscape.
Keloids are a growth of extra scar tissue where the skin has healed after an injury. Symptoms include flesh-colored, red, or pink, lumpy (nodular) or ridged, irritated from friction such as rubbing on clothing and tender and itchy. Risk factors include age and family history. Treatment includes corticosteroid, radiation, surgical removal and silicone gel or patches.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keloids - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Keloids (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Keloids (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Keloids and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Preclinical, Discovery and Unknown stages are 3, 5, 1 and 2 respectively.
Keloids (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keloids - Drugs In Development, 2021, provides an overview of the Keloids (Dermatology) pipeline landscape.
Keloids are a growth of extra scar tissue where the skin has healed after an injury. Symptoms include flesh-colored, red, or pink, lumpy (nodular) or ridged, irritated from friction such as rubbing on clothing and tender and itchy. Risk factors include age and family history. Treatment includes corticosteroid, radiation, surgical removal and silicone gel or patches.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keloids - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Keloids (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Keloids (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Keloids and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Preclinical, Discovery and Unknown stages are 3, 5, 1 and 2 respectively.
Keloids (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Keloids (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Keloids (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Keloids (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Keloids (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Keloids (Dermatology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Keloids (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Keloids (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Keloids - Overview
Keloids - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Keloids - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Keloids - Companies Involved in Therapeutics Development
CellionBioMed Inc
FirstString Research Inc
Lemonex Inc
Next Science Ltd
siRNAgen Therapeutics Corp
Sirnaomics Inc
Thirona Bio Inc
Topadur Pharma AG
Tumorend LLC
Viridian Therapeutics Inc
Yuhan Corp
Keloids - Drug Profiles
Antisense RNAi Oligonucleotide to Inhibit Amphiregulin for Hypertrophied scar and Keloid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBM-C1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CM-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Keloids - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FBM-5712 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Granexin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LEM-S401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
remlarsen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STP-705 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOPN-44 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YHC-1113 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Keloids - Dormant Projects
Keloids - Discontinued Products
Keloids - Product Development Milestones
Featured News & Press Releases
Jul 14, 2021: Sirnaomics doses first patient in phase 2 study of STP705 for keloid scar prevention
Apr 18, 2021: Sirnaomics initiates phase 2 study using STP705 for keloid scar prevention
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Keloids - Overview
Keloids - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Keloids - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Keloids - Companies Involved in Therapeutics Development
CellionBioMed Inc
FirstString Research Inc
Lemonex Inc
Next Science Ltd
siRNAgen Therapeutics Corp
Sirnaomics Inc
Thirona Bio Inc
Topadur Pharma AG
Tumorend LLC
Viridian Therapeutics Inc
Yuhan Corp
Keloids - Drug Profiles
Antisense RNAi Oligonucleotide to Inhibit Amphiregulin for Hypertrophied scar and Keloid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBM-C1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CM-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Keloids - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FBM-5712 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Granexin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LEM-S401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
remlarsen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STP-705 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOPN-44 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YHC-1113 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Keloids - Dormant Projects
Keloids - Discontinued Products
Keloids - Product Development Milestones
Featured News & Press Releases
Jul 14, 2021: Sirnaomics doses first patient in phase 2 study of STP705 for keloid scar prevention
Apr 18, 2021: Sirnaomics initiates phase 2 study using STP705 for keloid scar prevention
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Keloids, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Keloids - Pipeline by CellionBioMed Inc, 2021
Keloids - Pipeline by FirstString Research Inc, 2021
Keloids - Pipeline by Lemonex Inc, 2021
Keloids - Pipeline by Next Science Ltd, 2021
Keloids - Pipeline by siRNAgen Therapeutics Corp, 2021
Keloids - Pipeline by Sirnaomics Inc, 2021
Keloids - Pipeline by Thirona Bio Inc, 2021
Keloids - Pipeline by Topadur Pharma AG, 2021
Keloids - Pipeline by Tumorend LLC, 2021
Keloids - Pipeline by Viridian Therapeutics Inc, 2021
Keloids - Pipeline by Yuhan Corp, 2021
Keloids - Dormant Projects, 2021
Keloids - Discontinued Products, 2021
Number of Products under Development for Keloids, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Keloids - Pipeline by CellionBioMed Inc, 2021
Keloids - Pipeline by FirstString Research Inc, 2021
Keloids - Pipeline by Lemonex Inc, 2021
Keloids - Pipeline by Next Science Ltd, 2021
Keloids - Pipeline by siRNAgen Therapeutics Corp, 2021
Keloids - Pipeline by Sirnaomics Inc, 2021
Keloids - Pipeline by Thirona Bio Inc, 2021
Keloids - Pipeline by Topadur Pharma AG, 2021
Keloids - Pipeline by Tumorend LLC, 2021
Keloids - Pipeline by Viridian Therapeutics Inc, 2021
Keloids - Pipeline by Yuhan Corp, 2021
Keloids - Dormant Projects, 2021
Keloids - Discontinued Products, 2021
LIST OF FIGURES
Number of Products under Development for Keloids, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021
Number of Products under Development for Keloids, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021